Novel Biomarkers for Chronic Myelogenous Leukemia (CML)

Summary A high-dimensional metabolomics screen to diagnose and monitor chronic myeloid leukemia (CML) has been developed. Over 3000 metabolites are detected to yield a ‘cytogenetic signature’ that confirms the presence of cells bearing the Philadelphia chromosome, a genetic marker for CML. Through comparison of the levels of these metabolites to those found in the blood of disease-free individuals, diagnosis can be made as to the presence and severity of the cancer using only one blood sample. This rapid and sensitive analytic technology reduces time and overall cost associated with CML diagnosis and enhances patient comfort and well-being.

Applications Contact Maryanne Fenerjian, PhD Office of Technology Development Tel: 617-432-3845 Email: maryanne_fenerjian@harvard.edu For Further Information Please Contact the Director of Business Development Alex Szidon Email: alex_szidon@harvard.edu Telephone: (617) 495-3067

Inventor(s): Halperin, Jose A.

Type of Offer: Licensing



« More Diagnostic Patents

Share on      


CrowdSell Your Patent